QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study 期刊论文 2019, 卷号: 12, 页码: 745-757 作者:  Wu, Xiaoning;  Zhou, Jialing;  Xie, Wen;  Ding, Huiguo;  Ou, Xiaojuan 收藏  |  浏览/下载：32/0  |  提交时间：2020/01/03 entecavir  de novo combination  lamivudine  adefovir  compensated HBV-related cirrhosis  real-world  virological breakthrough   On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis 期刊论文 LIVER INTERNATIONAL, 2018, 卷号: 38, 期号: 6 作者:  Wu, Shanshan;  Kong, Yuanyuan;  Piao, Hongxin;  Jiang, Wei;  Xie, Wen 收藏  |  浏览/下载：18/0  |  提交时间：2019/12/05 dynamic change  HBV-related compensated cirrhosis  liver-related events  liver stiffness   Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study 期刊论文 EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 卷号: 18 作者:  Wu, Xiaoning;  Shi, Yiwen;  Zhou, Jialing;  Sun, Yameng;  Piao, Hongxin 收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05 Hepatitis B virus  liver cirrhosis  hepatocellular carcinoma  immune regulator  thymosin alpha-1  Ta-1   Is there any rule for antiviral therapy in HBV-related compensated cirrhosis patients with serum HBV DNA undetectable or at low levels and normal ALT? 会议论文 作者:  Yan, Taotao;  Sha, Xiaoying;  Wang, Jing;  Jin, Li;  Zhang, Yu 收藏  |  浏览/下载：15/0  |  提交时间：2019/12/02